Prosthesis (i.e. – artificial body members) – parts thereof – or ai – Arterial prosthesis – Stent structure
Patent
1997-05-21
1999-02-02
Geist, Gary
Prosthesis (i.e., artificial body members), parts thereof, or ai
Arterial prosthesis
Stent structure
562621, 549 65, C07C23570, C07D33332
Patent
active
058667172
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to therapeutically active hydroxamic acid and carboxylic acid derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to the use of such compounds in medicine. In particular, the compounds are inhibitors of metalloproteinases involved in tissue degradation, and in addition are inhibitors of the release of tumour necrosis factor from cells.
BACKGROUND TO THE INVENTION
Compounds which have the property of inhibiting the action of metalloproteinases involved in connective tissue breakdown such as collagenase, stromelysin and gelatinase (known as "matrix metalloproteinases", and herein referred to as MMPs) are thought to be potentially useful for the treatment or prophylaxis of conditions involving such tissue breakdown, for example rheumatoid arthritis, osteoarthritis, osteopenias such as osteoporosis, periodontitis, gingivitis, corneal epidermal or gastric ulceration, and tumour metastasis, invasion and growth. MMP inhibitors are also of potential value in the treatment of neuroinflammatory disorders, including those involving myelin degradation, for example multiple sclerosis, as well as in the management of angiogenesis dependent diseases, which include arthritic conditions and solid tumour growth as well as psoriasis, proliferative retinopathies, neovascular glaucoma, ocular tumours, angiofibromas and hemangiomas. However, the relative contributions of individual MMPs in any of the above disease states is not yet fully understood.
Metalloproteinases are characterised by the presence in the structure of a zinc(II) ion at the active site. It is now known that there exists a range of metalloproteinase enzymes that includes fibroblast collagenase (Type 1), PMN-collagenase, 72 kDa-gelatinase, 92 kDa-gelatinase, stromelysin, stromelysin-2 and PUMP-1 (J. F. Woessner, FASEB J, 1991, 5, 2145-2154). Many known MMP inhibitors are peptide derivatives, based on naturally occuring amino acids, and are analogues of the cleavage site in the collagen molecule. Chapman et al J. Med. Chem. 1993, 36, 4293-4301 report some general structure/activity findings in a series of N-carboxyalkyl peptides. Other known MMP inhibitors are less peptidic in structure, and may more properly be viewed as pseudopeptides or peptide mimetics. Such compounds usually having a functional group capable of binding to the zinc (II) site in the MMP, and known classes include those in which the zinc binding group is a hydroxamic acid, carboxylic acid, sulphydryl, and oxygenated phosphorus (eg phosphinic acid and phosphonic acid) groups.
Two known classes of pseudopeptide or peptide mimetic MMP inhibitors have a hydroxamic acid group or a carboxylic group respectively as their zinc binding groups. With a few exceptions, such known MMPs may be represented by the structural formula (I) ##STR2## in which X is the zinc binding hydroxamic acid (--CONHOH) or carboxylic acid (--COOH) group and the groups R.sub.1 to R.sub.5 are variable in accordance with the specific prior art disclosures of such compounds. Examples of patent publications disclosing such structures are given below.
In such compounds, it is generally understood in the art that variation of the zinc binding group and the substituents R.sub.1, R.sub.2 and R.sub.3 can have an appreciable effect on the relative inhibition of the metalloproteinase enzymes. The group X is thought to interact with metalloproteinase enzymes by binding to a zinc(II) ion in the active site. Generally the hydroxamic acid group is preferred over the carboxylic acid group in terms of inhibitory activity against the various metalloproteinase enzymes. However, the carboxylic acid group in combination with other substituents can provide selective inhibition of gelatinase (EP-489,577-A). The R.sub.1, R.sub.2 and R.sub.3 groups are believed to occupy respectively the P1, P1' and P2' amino acid side chain binding sites for the natural enzyme substrate. There is evidence that a larger R.sub.1 substituent can enhance activity against stromelysin, and tha
REFERENCES:
patent: 3468936 (1969-09-01), van der Burg
patent: 4599361 (1986-07-01), Dickens et al.
patent: 4996358 (1991-02-01), Handa et al.
patent: 5183900 (1993-02-01), Galardy et al.
patent: 5256657 (1993-10-01), Singh et al.
patent: 5270326 (1993-12-01), Galardy et al.
patent: 5300501 (1994-04-01), Porter et al.
patent: 5300674 (1994-04-01), Crimmin et al.
patent: 5304549 (1994-04-01), Broadhurst et al.
patent: 5569665 (1996-10-01), Porter et al.
patent: 5643964 (1997-07-01), Dickens et al.
Conway et al, The Journal of Experimental Medicine, vol. 182, pp. 449-457, Aug. 1995.
DiMartino et al, Annals of the New York Academy of Sciences, vol. 732, pp. 411-413, 1994.
Gijbels et al, J. Clin. Invest., vol. 94, No. 6, pp. 2177-2182, Dec. 1994.
Beckett Raymond Paul
Martin Fionna Mitchell
Miller Andrew
Whittaker Mark
British Biotech Pharmaceuticals Limited
Davis Brian J.
Geist Gary
LandOfFree
Metalloproteinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metalloproteinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metalloproteinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1118740